Since then, mutant KRAS has been identified as an important oncogenic driver for various types of solid malignancies (e.g., NSCLC, pancreatic and colorectal cancer) [23] that promotes cancer initiation, maintenance and progression in genetically engineered mouse models (GEMMs) [24,25,26]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.